Eversept Partners LP Reduces Stock Holdings in uniQure N.V. $QURE

Eversept Partners LP lowered its position in uniQure N.V. (NASDAQ:QURE) by 92.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,820 shares of the biotechnology company’s stock after selling 814,553 shares during the period. Eversept Partners LP’s holdings in uniQure were worth $1,503,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in QURE. Jones Financial Companies Lllp increased its stake in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the period. Arizona State Retirement System increased its stake in uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares during the period. Ensign Peak Advisors Inc increased its stake in uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the period. Finally, FNY Investment Advisers LLC increased its stake in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the period. Institutional investors own 78.83% of the company’s stock.

Insider Activity at uniQure

In related news, Director Rachelle Suzanne Jacques sold 1,993 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58. Following the completion of the transaction, the director owned 33,903 shares of the company’s stock, valued at $917,415.18. This trade represents a 5.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David D. Meek sold 1,993 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the transaction, the director directly owned 39,747 shares of the company’s stock, valued at approximately $1,075,553.82. This trade represents a 4.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 101,054 shares of company stock worth $2,655,791 in the last quarter. 4.65% of the stock is owned by insiders.

Analysts Set New Price Targets

QURE has been the subject of a number of analyst reports. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a report on Tuesday, March 3rd. TD Cowen restated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Finally, Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective for the company in a research note on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $47.17.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure said it plans to submit a BLA for AMT-130 in Huntington’s disease after the FDA indicated the company’s three-year data may support accelerated approval, a major regulatory win that could speed the drug toward market. Article Title
• Positive Sentiment: Analysts turned more constructive after the FDA update, with Cantor Fitzgerald upgrading QURE to overweight and lifting its price target, reinforcing the market’s bullish reaction. Article Title
• Positive Sentiment: Options activity also picked up, with traders buying unusually large volumes of call options, suggesting strong speculative demand tied to the FDA catalyst. Article Title

uniQure Stock Performance

Shares of QURE opened at $48.16 on Thursday. The stock has a 50-day moving average of $23.55 and a two-hundred day moving average of $21.90. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The stock has a market cap of $3.04 billion, a P/E ratio of -13.84 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. As a group, research analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.